Clinical Trials
Hummingbird Bioscience is dedicated to ensuring that patients receive the maximum benefit from our treatments. The company has dedicated resources over the years in understanding the underlying biology of different cancers and creating antibody therapeutics that will best suit patients. Our clinical trial design is biomarker-driven and we work with globally-recognized partners to obtain clinically-relevant data to ensure the best patient profile match for our therapies. For more information on our clinical trials, please reach out to patients@hummingbirdbio.com.
Hummingbird Bioscience is recruiting for a Phase Ib/II study of HMBD-001 in squamous cell cancers. Squamous cell cancer is a type of cancer that starts in the topmost layer of cells in many parts of the body, including the mouth, nose, throat, lungs and cervix.
HMBD-001 is a novel targeted treatment currently in clinical testing. Clinical trial details: Study Details | Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers | ClinicalTrials.gov
If you have been diagnosed with squamous cell cancer, please speak with your oncologist. You may be eligible for clinical trials that are testing experimental treatments for these cancers. Please reach out to patients@hummingbirdbio.com for more information.
